Compare MPLT & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPLT | AGMB |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 811.3M | 677.9M |
| IPO Year | N/A | N/A |
| Metric | MPLT | AGMB |
|---|---|---|
| Price | $24.19 | $9.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $32.67 | $32.00 |
| AVG Volume (30 Days) | ★ 194.6K | 148.1K |
| Earning Date | 05-28-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.24 | $9.63 |
| 52 Week High | $24.15 | $17.45 |
| Indicator | MPLT | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 75.09 | 36.77 |
| Support Level | $16.19 | N/A |
| Resistance Level | N/A | $12.81 |
| Average True Range (ATR) | 1.56 | 1.68 |
| MACD | 0.64 | -0.09 |
| Stochastic Oscillator | 83.57 | 7.30 |
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.